Demographics and pretreatment characteristics of patients receiving initial flavopiridol therapy, N = 52
| . | No. . | Range . |
|---|---|---|
| Demographics | ||
| Sex, no. | ||
| Male | 38 | |
| Female | 14 | |
| Mean age, y (median) | 60 (60) | 38-84 |
| Mean weight, kg (median) | 82 (83) | 52-121 |
| Body surface area, m2, mean (median) | 2 (1.95) | 1.54-2.41 |
| Disease characteristics (%) | ||
| Lymphocyte count | ||
| More than 5000 (CLL) | 43 | |
| Less than 5000 (SLL) | 9 | |
| Rai stage III/IV | 42 (81) | |
| Bulky lymph nodes larger than 5 cm | 38 (73) | |
| Median prior therapies | 4 | 1-14 |
| Prior fludarabine therapy | 51 (98) | |
| Fludarabine refractory | 43 (83) | |
| Cytogenetics (%) | ||
| del(11q22) | 19 (37) | |
| del(17p13) | 18 (35) | |
| Complex karyotype | 25 (48) | |
| Baseline CBC | ||
| Platelets, ×109/L | 105 (106) | 6-284 |
| White blood cells, ×109/L | 59 (16.6) | 1.9-314.5 |
| Hemoglobin, mM | 10.5 (10.2) | 5.8-15.4 |
| Albumin, g/dL | 3.5 (3.4) | 2.6-4.7 |
| Protein, g/dL | 5.7 (5.6) | 4.4-8.5 |
| . | No. . | Range . |
|---|---|---|
| Demographics | ||
| Sex, no. | ||
| Male | 38 | |
| Female | 14 | |
| Mean age, y (median) | 60 (60) | 38-84 |
| Mean weight, kg (median) | 82 (83) | 52-121 |
| Body surface area, m2, mean (median) | 2 (1.95) | 1.54-2.41 |
| Disease characteristics (%) | ||
| Lymphocyte count | ||
| More than 5000 (CLL) | 43 | |
| Less than 5000 (SLL) | 9 | |
| Rai stage III/IV | 42 (81) | |
| Bulky lymph nodes larger than 5 cm | 38 (73) | |
| Median prior therapies | 4 | 1-14 |
| Prior fludarabine therapy | 51 (98) | |
| Fludarabine refractory | 43 (83) | |
| Cytogenetics (%) | ||
| del(11q22) | 19 (37) | |
| del(17p13) | 18 (35) | |
| Complex karyotype | 25 (48) | |
| Baseline CBC | ||
| Platelets, ×109/L | 105 (106) | 6-284 |
| White blood cells, ×109/L | 59 (16.6) | 1.9-314.5 |
| Hemoglobin, mM | 10.5 (10.2) | 5.8-15.4 |
| Albumin, g/dL | 3.5 (3.4) | 2.6-4.7 |
| Protein, g/dL | 5.7 (5.6) | 4.4-8.5 |